New treatment approaches to indolent non-Hodgkin's lymphoma

被引：15

作者：

Seymour, JF ^{[1
]}

机构：

[1] Peter MacCallum Canc Inst, Dept Hematol, Melbourne, Vic 3002, Australia

来源：

SEMINARS IN ONCOLOGY | 2004年 / 31卷 / 01期

关键词：

D O I：

10.1053/j.seminoncol.2003.12.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：27 / 32

页数：6

共 25 条

[1] Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden:: clinical and molecular evaluation [J].

Colombat, P ;

Salles, G ;

Brousse, N ;

Eftekhari, P ;

Soubeyran, P ;

Delwail, V ;

Deconinck, E ;

Haïoun, C ;

Foussard, C ;

Sebban, C ;

Stamatoullas, A ;

Milpied, N ;

Boué, F ;

Taillan, B ;

Lederlin, P ;

Najman, A ;

Thièblemont, C ;

Montestruc, F ;

Mathieu-Boué, A ;

Benzohra, A ;

Solal-Céligny, P .

BLOOD, 2001, 97 (01) :101-106

[2]

Czuczman MS, 2001, BLOOD, V98, p601A

[3] Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy [J].

Czuczman, MS ;

Grillo-López, AJ ;

White, CA ;

Saleh, M ;

Gordon, L ;

LoBuglio, AF ;

Jonas, C ;

Klippenstein, D ;

Dallaire, B ;

Varns, C .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :268-276

[4] Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma:: Results of a phase II trial of rituximab [J].

Davis, TA ;

White, CA ;

Grillo-López, AJ ;

Velásquez, WS ;

Link, B ;

Maloney, DG ;

Dillman, RO ;

Williams, ME ;

Mohrbacher, A ;

Weaver, R ;

Dowden, S ;

Levy, R .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) :1851-1857

[5] Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:: Safety and efficacy of re-treatment [J].

Davis, TA ;

Grillo-López, AJ ;

White, CA ;

McLaughlin, P ;

Czuczman, MS ;

Link, BK ;

Maloney, DG ;

Weaver, RL ;

Rosenberg, J ;

Levy, R .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3135-3143

[6]

DEMIDEM A, 1995, FASEB J, V9, pA206

[7] Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs [J].

Demidem, A ;

Lam, T ;

Alas, S ;

Hariharan, K ;

Hanna, N ;

Bonavida, B .

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1997, 12 (03) :177-186

[8]

DREYLING MH, 2003, HEMATOL J S2, V4, P150

[9] Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma [J].

Freedman, AS ;

Neuberg, D ;

Mauch, P ;

Soiffer, RJ ;

Anderson, KC ;

Fisher, DC ;

Schlossman, R ;

Alyea, EP ;

Takvorian, T ;

Jallow, H ;

Kuhlman, C ;

Ritz, J ;

Nader, LM ;

Gribben, JG .

BLOOD, 1999, 94 (10) :3325-3333

[10]

Ghielmini M, 2002, BLOOD, V100, p161A

← 1 2 3 →